Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'

Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'

A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is in...

Full description

Bibliographic Details
Main Authors: Raman Sharma, Chao Chen, Lionel Tan, Katie Rolfe, Ioana-Gabriela Fiţa, Siôn Jones, Anup Pingle, Rachel A Gibson, Navin Goyal, Hema Sharma, Panayota Bird
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2024-02-01
Series:eLife
Subjects:
tafenoquine
plasmodium vivax malaria
radical cure
haemolysis
Online Access:https://elifesciences.org/articles/89263

Internet

https://elifesciences.org/articles/89263

Similar Items